Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iodine I 131 IPA

A radioconjugate consisting of the tumor-specific amino acid derivative 4-iodo-L-phenylalanine labeled with iodine I 131, a beta emitting radionuclide, with potential antineoplastic activity. Upon administration, iodine I 131 IPA actively crosses the blood-brain barrier and accumulates specifically in gliomas, via the amino acid transport system l-amino acid transporter 1 (LAT1) over-expressed in malignant glioma cells. where it delivers a cytotoxic dose of beta radiation. Cells that are exposed to radiation may also release potent toxins into the intracellular environment, leading to radiation-induced biological bystander effects (RIBBE) and killing cells not directly exposed to the radiation. Iodine I 131 IPA may also act synergistically with external irradiation due to its radiosensitizing property.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:131I-IPA
4-[131I]iodo-L-phenylalanine
4-L-[131I]iodo-phenylalanine
I-131 IPA
iodine-131 IPA
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search